Foreign direct investment CFIUS review
Healthcare and life sciences companies are under sustained scrutiny from the Committee on Foreign Investment in the United States, which has expanded its mandatory declaration requirements for foreign acquisitions of U.S. businesses with ties to sensitive health data, biotech IP, and medical supply chains under the 2018 Foreign Investment Risk Review Modernization Act and its 2020 implementing regulations. The U.S. Department of Health and Human Services holds concurrent authority as a lead agency in CFIUS reviews touching regulated health sectors, meaning deal timelines now carry a second federal clearance variable that many transaction teams still underprice. Short-form declarations, 30-day review windows, and the real possibility of mitigation agreements or divestiture orders are the working reality for any inbound deal involving genomics, pharmaceutical manufacturing, or patient data infrastructure.
Watch
- FIRRMA TID U.S. business designation: does your target qualify under 31 CFR Part 800?
- Mandatory CFIUS declaration threshold for foreign government-linked investors in biotech
- Mitigation agreement precedents requiring data localization for health record platforms
- HHS referral pattern in reviews involving pharmaceutical supply chain dependencies on China or Russia
- Proposed updates to CFIUS covered transaction rules circulating in the 2024-2025 rulemaking docket
Recent material activity in Healthcare & Life Sciences
Active monitoring in place across Healthcare & Life Sciences. Material developments related to foreign direct investment cfius review will appear here as they are published.